Combination of resveratrol and 5-azacytydine improves osteogenesis of metabolic syndrome mesenchymal stem cells

J Cell Mol Med. 2018 Oct;22(10):4771-4793. doi: 10.1111/jcmm.13731. Epub 2018 Jul 12.

Abstract

Endocrine disorders have become more and more frequently diagnosed in humans and animals. In horses, equine metabolic syndrome (EMS) is characterized by insulin resistance, hyperleptinemia, hyperinsulinemia, inflammation and usually by pathological obesity. Due to an increased inflammatory response in the adipose tissue, cytophysiological properties of adipose derived stem cells (ASC) have been impaired, which strongly limits their therapeutic potential. Excessive accumulation of reactive oxygen species, mitochondria deterioration and accelerated ageing of those cells affect their multipotency and restrict the effectiveness of the differentiation process. In the present study, we have treated ASC isolated from EMS individuals with a combination of 5-azacytydine (AZA) and resveratrol (RES) in order to reverse their aged phenotype and enhance osteogenic differentiation. Using SEM and confocal microscope, cell morphology, matrix mineralization and mitochondrial dynamics were assessed. Furthermore, we investigated the expression of osteogenic-related genes with RT-PCR. We also investigated the role of autophagy during differentiation and silenced PARKIN expression with siRNA. Obtained results indicated that AZA/RES significantly enhanced early osteogenesis of ASC derived from EMS animals. Increased matrix mineralization, RUNX-2, collagen type I and osteopontin levels were noted. Furthermore, we proved that AZA/RES exerts its beneficial effects by modulating autophagy and mitochondrial dynamics through PARKIN and RUNX-2 activity.

Keywords: adipose stem cells; ageing; autophagy; metabolic syndrome; mitochondria; osteogenic differentiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Adipose Tissue / pathology
  • Animals
  • Autophagy / drug effects
  • Autophagy / genetics
  • Azacitidine / pharmacology*
  • Cell Differentiation / drug effects
  • Cellular Senescence / drug effects
  • Collagen Type I / agonists
  • Collagen Type I / genetics
  • Collagen Type I / metabolism
  • Core Binding Factor Alpha 1 Subunit / agonists
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • Drug Combinations
  • Female
  • Gene Expression Regulation
  • Horse Diseases / drug therapy*
  • Horse Diseases / genetics
  • Horse Diseases / pathology
  • Horses
  • Insulin Resistance
  • Male
  • Mesenchymal Stem Cells / drug effects*
  • Mesenchymal Stem Cells / metabolism
  • Mesenchymal Stem Cells / pathology
  • Metabolic Syndrome / drug therapy
  • Metabolic Syndrome / genetics
  • Metabolic Syndrome / pathology
  • Metabolic Syndrome / veterinary*
  • Mitochondrial Dynamics / drug effects
  • Obesity / drug therapy
  • Obesity / genetics
  • Obesity / pathology
  • Obesity / veterinary*
  • Osteoblasts / cytology
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism
  • Osteogenesis / drug effects*
  • Osteogenesis / genetics
  • Osteopontin / agonists
  • Osteopontin / genetics
  • Osteopontin / metabolism
  • Oxidative Stress
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Resveratrol / pharmacology*
  • Signal Transduction
  • Ubiquitin-Protein Ligases / antagonists & inhibitors
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Collagen Type I
  • Core Binding Factor Alpha 1 Subunit
  • Drug Combinations
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Osteopontin
  • Ubiquitin-Protein Ligases
  • parkin protein
  • Azacitidine
  • Resveratrol